Trial Profile
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 May 2023
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary) ; Etanercept
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms Ixora-peds
- Sponsors Eli Lilly and Company
- 21 Mar 2023 Results of post-hoc pooled analysis assessing the disease improvement and clearance of palmoplantar PsO in the palms and soles of patients with moderate-to-severe plaque PsO and baseline palmoplantar PsO who were treated with ixekizumab for up to 5 years across 6 clinical trials (NCT01474512, NCT01597245, NCT01646177, NCT03364309, NCT02561806 and NCT03073200), presented at the American Academy of Dermatology annual Meeting 2023.
- 21 Mar 2023 Results assessing to compare the efficacy of ixekizumab versus secukinumab in pediatric patients with severe plaque psoriasis from IXORA-PEDS and CAIN457A2310 using matching-adjusted indirect comparison, presented at the American Academy of Dermatology annual Meeting 2023.
- 13 Apr 2022 Results assessing long-term efficacy and safety of Up to 108 Weeks of Ixekizumab published in the JAMA Dermatology